Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03940352
Title HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals

acute myeloid leukemia

myelodysplastic syndrome


HDM201 + Venetoclax

HDM201 + Sabatolimab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST